Your dog was diagnosed with Chemodectoma (Aortic Body / Heart Base Tumour). Uncommon tumour of chemoreceptor tissue at the heart base. Slow-growing but can cause pericardial effusion and tamponade. Brachycephalic breeds are predisposed (chronic hypoxia theory). Low-moderate metastatic rate (~13%). Compare 3 treatment options for dogs including Toceranib Phosphate (Palladia), Pericardiectomy, Stereotactic Body Radiation Therapy (SBRT) — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Chemodectoma (Aortic Body / Heart Base Tumour)
Canine Oncology Treatment Guide
Chemodectoma (Aortic Body / Heart Base Tumour)
Neuroendocrine
About This Cancer
Chemodectoma (also called aortic body tumour or paraganglioma) arises from chemoreceptor cells at the base of the heart. These specialised cells normally monitor blood oxygen and carbon dioxide levels. The tumour is strongly associated with brachycephalic breeds — Boxers, Bulldogs, and Boston Terriers — and it has been hypothesised that the chronic mild oxygen deficiency associated with their flattened airways may stimulate overgrowth of these monitoring cells. Chemodectomas are generally slow-growing, and many dogs live for extended periods with the tumour. The main clinical problem arises when the tumour causes fluid to accumulate in the pericardial sac, leading to compression of the heart. The tumour has relatively low metastatic potential (about 13%), and treatment focuses on managing complications rather than necessarily removing the tumour itself.
No formal staging system
Assessment based on tumour size, presence of pericardial effusion, arrhythmias, vena caval obstruction, and regional or distant metastasis.
Prognostic Factors(2)
Minimum Workup(6 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.